PMH3 FATORS ASSOCIATED WITH SECOND-GENERATION ANTIPSYCHOITC USE IN THE CALIFORNIA MEDICAID (MEDI-CAL) PATIENTS WITH SCHIZOPHRENIA  by Chen, L & McCombs, JS
264 Abstracts
OBJECTIVES: To investigate the relationship between gaps in
oral antipsychotic therapy and risk of hospitalization in the 
outpatient treatment of schizophrenia within a managed-care
environment. METHODS: A retrospective evaluation of schizo-
phrenia patients from a mental health subset of managed care
(PHARMetrics) data was conducted. Patients were required 
to be continuously eligible for 13 months following their index
date (i.e., ﬁrst claim date during the enrollment period between
January 1, 2000–December 31, 2001), and were followed for 12
months post-index. Inclusion criteria included a diagnosis of
schizophrenia and at least one claim of an oral antipsychotic in
1999 and two in 2000 or 2001. Exclusion criteria included
bipolar disorder, claims for long-term care, and long-acting
antipsychotics. Medication compliance measures included
maximum gap in therapy, medication possession ratio (MPR),
consistence, and persistence. Logistic regression was used to
analyze the odds of being hospitalized. Independent variables
included compliance, age, and sex. RESULTS: Of the 1499 sub-
jects included in the study (mean [SD] age = 45.1 ± 12.4 years;
46.6% were male), 5.9% were hospitalized at least once. The
odds of hospitalization in this population rose by 2.1% for every
5-day increase in therapy gap (p = 0.0004) based on a continu-
ous model. Patients with >30-day maximum gap in their med-
ication had higher odds (4.66, p < 0.0001) of hospitalization
than the 0 to 10 day reference group. The 11 to 30 day gap group
approached signiﬁcance with an odds ratio of 2.10 (p =
0.05769). MPR and consistence models indicated that the odds
of hospitalization decrease by a factor of 0.831 (p < 0.0001) and
0.812 (p < 0.0001) for a 10% increment in MPR and consis-
tence respectively. Age was a signiﬁcant predictor of hospital-
ization in all models. Persistence and gender were not signiﬁcant
predictors. CONCLUSIONS: Gaps in oral antipsychotic treat-
ment are associated with an increased risk of hospitalization in
schizophrenic patients.
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OBJECTIVE: Olanzapine and risperidone are the two most
widely used second-generation antipsychotic medications by Cal-
ifornia Medicaid (Medi-Cal) patients with severe mental disor-
ders. This analysis investigates the factors associated medication
choice for Medi-Cal patients with schizophrenia who restart
therapy after a break in treatment. METHOD: Paid claims data
were analyzed to identify antipsychotic ‘re-starter’ treatment
episodes initiated between January 1999 and March 2003. An
episode was deﬁned each time a patient re-started therapy on a
new medication or the same drug after a break of 15 days or
more. Re-starter episodes with either olanzapine or risperidone
only were selected if 6 months of pre-treatment and 12 months
of post-treatment data were available. Multivariate logistic
regression was used to determine the factors that affected treat-
ment choice. RESULTS: A total of 186,338 re-starter treatment
episodes met study selection criteria (56% olanzapine). Mean
age was 44 years; mean duration of uninterrupted therapy 
was 135 days. Patients 35–65 years of age were between 6% to
9% more likely to receive olanzapine, as were male patients
(+21%) and patients with a prior psychiatric hospitalization
(+4%). The likelihood of using olanzapine increased with the
prior use of non-institutional care. Risperidone patients were
more likely to be urban residents (+5%), classiﬁed as disabled
(+6%), supplemental security income (+17%) or AFDC (+6%)
eligible, Hispanic (+12%), black (+10%), diabetic (+22%) and
have a history of prior nursing home use (+14%). Risperidone
patients were more likely to be age 65–75 (+7%) or 75+ (+19%),
with no differences observed in the under 35 population (p <
0.05 for all results). CONCLUSION: Physicians in California
used olanzapine and risperidone differentially to treat patients
with schizophrenia. The observed differences in patient charac-
teristics for olanzapine and risperidone patients may affect both
treatment outcomes and post-treatment costs and must be
adjusted for before comparing the outcomes achieved using 
these agents.
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OBJECTIVES: To assess one-year medication adherence and per-
sistence among schizophrenia clients who initiated therapy with
olanzapine, quetiapine or risperidone. METHODS: Indiana
Medicaid Program enrollees were included in this analysis if they
were diagnosed with schizophrenia (ICD9-295); initiated olan-
zapine (n = 711), quetiapine (n = 292) or risperidone (n = 602)
between January 1, 1999 and December 31, 2000; had not
received the three atypicals in the year prior-initiation; and non-
institutionalized and continuously enrolled 1-year prior and 1-
year post the initiation. Descriptive and multiple analyses were
used to compare olanzapine, quetiapine and risperidone groups
on three outcome measures: adherence rates (percent days of
medication possession); persistence (continuous treatment days);
and the likelihood of switching/augmenting the other medica-
tions of interest, by controlling for demographics, comorbidities,
and prior medication use patterns. RESULTS: Individuals initi-
ated on olanzapine had a statistically signiﬁcantly higher adher-
ence rate (59.1%) than those receiving quetiapine (52.0%, p <
0.007) or risperidone (54.4%, p < 0.037), and a signiﬁcantly
longer persistence (153 days) than those treated with quetiapine
(135 days, p < 0.001) or risperidone (140 days, p < 0.001). Olan-
zapine patients also were less likely to switch and/or augment
(17.6%) than quetiapine patients (26.0%, p < 0.032). Adher-
ence, persistence and likelihood of switch/augmentation didn’t
signiﬁcantly differ between patients initiated on quetiapine and
risperidone. CONCLUSION: Compared to quetiapine or risperi-
done, olanzapine was associated with better adherence and per-
sistence among individuals with schizophrenia.
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